![Leveraging COVID-19 Testing Infrastructure Can Boost Diabetes Screening](https://www.g2intelligence.com/wp-content/uploads/2022/06/July22.DTET_.COVID_.Diabetes-iStock-1800x1250-2-1080x675.jpg)
Leveraging COVID-19 Testing Infrastructure Can Boost Diabetes Screening
A new study suggests that this is a viable idea, particularly in the context of diabetes screening in a Latinx community.
A new study suggests that this is a viable idea, particularly in the context of diabetes screening in a Latinx community.
The number of non-COVID-19 tests billed to Medicare during the pandemic has decreased compared to the six-month period before COVID-19.
The move comes shortly after the FDA said it was going to decline some pre-submission requests to focus on pandemic-related diagnostics.
New research led by the American Cancer Society shows decreases in cervical and breast cancer screening during the pandemic.
For the first time, the FDA has granted emergency use authorization for a test to differentiate strains of the SARS-CoV-2 virus.